alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells — alloSHRINK

Unresectable Metastatic Colorectal Cancer Clinical Trial

Official title:
An Open-label, Phase I Study to Assess the Safety of Multiple Doses of CYAD-101, Administered After Standard FOLFOX or FOLFIRI Chemotherapy in Patients With Unresectable Metastatic Colorectal Cancer

Status Recruiting

Clinical Trial Summary

The purpose of the alloSHRINK study is to assess the safety, cell kinetics and clinical activity of CYAD-101 in patients with unresectable metastatic colorectal cancer administered after standard chemotherapy

Clinical Trial Description

This Study aims to determine and confirm the recommended dose of the allogeneic CYAD-101 cells after standard FOLFOX or FOLFIRI chemotherapy in patients with unresectable metastatic colorectal cancer ;

Study Design

Related Conditions & MeSH terms

Colorectal Neoplasms
Unresectable Metastatic Colorectal Cancer

Clinical Trial Details

NCT number	NCT03692429
Study type	Interventional
Source	Celyad Oncology SA
Contact	Celyad Oncology Medical Monitor, MD, PhD
Phone	+3210394100
Email	clinicaltrials@celyad.com
Status	Recruiting
Phase	Phase 1
Start date	November 28, 2018
Completion date	February 17, 2036

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05068206` - A Clinical Study to Compare the Efficacy and Safety of AK105 Plus Anlotinib and Capecitabine/Oxaliplatin (CapeOx) , Anlotinib Plus CapeOx, Bevacizumab Plus CapeOx	Phase 2
Not yet recruiting	`NCT04131803` - Probiotics Combined With Standard Chemotherapy Plus Targeted Therapy in Patients With Metastatic Colorectal Cancer	N/A
Recruiting	`NCT04991948` - Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer	Phase 1
Recruiting	`NCT06107413` - Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab	Phase 2
Completed	`NCT01802684` - OPTIMOX-aflibercept as First-line Therapy in Patients With Unresectable Metastatic Colorectal Cancer	Phase 2
Recruiting	`NCT04160416` - mXELOXIRI Combined With Molecular Targeted Drug in mCRC	Phase 2
Recruiting	`NCT04866108` - A Phase II Study of Fruquintinib Combined With Capecitabine as First-line Treatment for Advanced Metastatic Colorectal Cancer Unsuitable for Intravenous Chemotherapy	Phase 2